In a phase 2 clinical trial, poziotinib was administered to patients with heavily pretreated HER2+ metastatic breast cancer who had previously undergone two HER2-targeted therapies, resulting in encouraging anti-cancer activity [145]. Here, ERBB2 is linked to cancer.